GIMBHI’s daily mental health update — 3/4/26

💰 Grow Therapy raises $150M Series D at $3B valuation with $1B in revenue (Behavioral Health Business) — 03/03/26 TL;DR: Grow Therapy secured $150M led by TCV and Goldman Sachs to deepen employer EAP partnerships and expand health system integrations nationwide.

🧩 Positive Development secures $45M to expand autism developmental therapy nationwide (Business Wire) — 01/13/26 TL;DR: Positive Development closed a $45M debt facility from SVB and Pinegrove to scale its lower-cost, relationship-based autism therapy across the U.S.

🤖 MMI launches FDA-approved trials using microrobots to treat Alzheimer’s (Forbes) — 03/03/26 TL;DR: MMI is trialing tiny surgical robots to clear brain drainage pathways in Alzheimer’s patients, targeting FDA approval by end of 2027.

🧠 Psychiatrist explains how objective digital tools sharpen adult ADHD diagnosis (Psychiatric Times) — 03/02/26 TL;DR: Dr. Jennie Byrne advocates combining computerized ADHD tests, clinical interviews, and rating scales for more accurate diagnosis and treatment tracking.

🧲 Salma Health launches from stealth with $80M to advance interventional psychiatry (Behavioral Health Business) — 03/03/26 TL;DR: Salma Health raised $80M Series A led by Mubadala Capital and ARCH Ventures to offer TMS, neuromodulation, and AI-driven brain health care across the U.S.

🧠 Ease Health raises $41M from a16z to unify behavioral health operations (Business Wire) — 03/02/26 TL;DR: Ease Health emerged from stealth with a $41M Series A to consolidate CRM, EHR, and RCM into one AI-native platform for behavioral health providers.